gms | German Medical Science

128. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

03.05. - 06.05.2011, München

The Regulation of Survivin Expression in Rectal Cancers during preoperative Radiochemotherapie and its Impact on Recurrence and Survival

Meeting Abstract

  • Thilo Sprenger - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen
  • Franz Rödel - Universitätsklinikum Frankfurt, Strahlentherapie und Onkologie, Frankfurt/Main
  • Tim Beissbarth - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen
  • Lena Conradi - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen
  • B. Michael Ghadimi - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen
  • Heinz Becker - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen
  • Claus Rödel - Universitätsklinikum Frankfurt, Strahlentherapie und Onkologie, Frankfurt/Main
  • Torsten Liersch - Universitätsmedizin Göttingen, Allgemein- und Viszeralchirurgie, Göttingen

Deutsche Gesellschaft für Chirurgie. 128. Kongress der Deutschen Gesellschaft für Chirurgie. München, 03.-06.05.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11dgch337

DOI: 10.3205/11dgch337, URN: urn:nbn:de:0183-11dgch3376

Veröffentlicht: 20. Mai 2011

© 2011 Sprenger et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction: Valid molecular markers need to be implemented in clinical trials to fulfill the demand of a risk-adapted and more individualized multimodal therapy of locally advanced primary rectal cancer. In the present study the expression of the inhibitor-of-apoptosis (IAP) protein Survivin was evaluated in pre-treatment biopsies and corresponding post-treatment resection specimens, and was correlated to histo- pathological tumor characteristics and clinical follow-up.

Materials and methods: 116 patients with stage II/III rectal cancer treated with 5-FU based neoadjuvant radiochemotherapy (RCT) at a single university medical centre within the German Rectal Cancer Trials were investigated. Survivin expression in pre-treatment biopsies and surgical resection specimens were determined by immunohistochemistry by two independent institutions and correlated with histopathologic parameters, tumor recurrences, disease-free and cancer-specific survival.

Results: In pre-treatment biopsies, a higher Survivin expression correlated with advanced ypT (p=0.026) and ypUICC (p=0.05) stage as well as decreased disease- free survival (p=0.038) after preoperative RCT. High post-treatment Survivin levels were associated with advanced ypT stage (p=0.03) and residual lymph node metastases (p=0.04). Moreover, neoadjuvant RCT resulted in a significant down-regulation of Survivin expression (p < 0.0001). A failure of RCT-induced down-regulation was associated with development of distant metastases (p=0.0056) and cancer-related death (p=0.026), and was significantly correlated with disease-free (p=0.011*/0.02**) and cancer- specific survival (p=0.0017*/0.01**) in uni* and multivariate** analyses.

Conclusion: Survivin expression in rectal cancer displays a marker with prognostic validity. These results underline the usefulness of Survivin to monitor individual response to RCT in rectal cancer, and encourage anti-Survivin strategies in multimodal rectal cancer therapy within future randomised clinical trials.